Perturbing of HIV Reservoir With Immune Stimulation
Perturbing the HIV Reservoir With Immune Stimulation
연구 개요
상세 설명
Title: Perturbing the HIV Reservoir
Sample Size: 56
Study Population: HIV-infected individuals between 18 and 65 years old who started similar antiretroviral therapy (ART) during chronic infection and remained virally suppressed for at least 48 weeks before enrollment. Participants will have CD4 >250 cells/μl at enrollment and a CD4 nadir >100 cells/μl.
Participating Sites: UCSD's Antiviral Research Center (AVRC)
Study Design: The proposed study is a randomized double-blinded control trial conducted over 28 weeks. Randomized interventions will be injections of Influenza vaccine, Pneumococcal vaccine, and Placebo. Each participant will receive each injection but in a randomized order.
Schedule of Evaluations: Study evaluations will be based on three 30 day cycles (Influenza vaccine, Pneumococcus vaccine, Placebo in random order) over 28 weeks of the RCT. Pre injection: one paired blood and genital secretion sample will be collected before each injection. Post-injection: paired blood and genital secretion samples will be collected on days 2, 4, 7, 14 and 30 after each injection.
Study Duration: 240 weeks
Study Regimen/Intervention: This is a double blind RCT of two vaccines (Pneumovax®23 and Fluarix®) plus placebo (sterile saline injection). Study participants will be followed for 28 weeks after enrollment. During this 28-week period, blood and genital secretion samples will be collected on day 0 and five subsequent time points after each injection (days 2, 4, 7, 14 and 30). Injections (vaccine or placebo) will be administered 12 weeks apart and in a random order, to minimize a possible bias due to the order of the vaccines.
Primary Objective: To determine the impact of Pneumococcus and Influenza vaccines on the HIV transcriptional activity in individuals who are virologically suppressed for at least 48 weeks on similar ART.
Primary Outcome: Average level of CD4+ T cell-associated HIV RNA transcription measured at days 2, 4, 7, 14 and 30 after each injection.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
California
-
San Diego, California, 미국, 92103-8208
- UCSD AntiViral Research Center (AVRC)
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- Documented HIV-1 infection more than 365 days ago (HIV antibody or viral load positive).
- Capable of signing written informed consent.
- Documented viral s suppression for at least 48 weeks (≤50 copies/mL)
- Men and women between 18 and 65 years of age.
- Read and comprehend English.
- Documented CD4 count at enrollment (>250 cells/µl)
- Reported CD4 nadir >100 cells/µl.
- Received seasonal flu vaccination at least 6 weeks prior to first trial injection (and not more recently)
- Received vaccination for pneumococcal disease at least 12 months prior to first trial injection (and not more recently)
- Started ART during chronic infection (> 6 months from estimated date of injection)
Exclusion Criteria
- Uncontrolled psychiatric condition.
- Under the influence of drug(s) or alcohol at time of screening.
- Any condition that, in the opinion of the investigator, would limit follow-up and adequate consent.
- History of allergic reactions to any of the proposed vaccines or egg allergy.
- History of Gullian Barre syndrome
- Receiving immunosuppressive medications.
- Pregnancy or lactation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Pneumococcal, then Influenza, then Placebo vaccination
Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
|
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).
|
|
다른: Pneumococcal, then Placebo, then Influenza vaccination
Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo).
After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
|
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).
|
|
다른: Influenza, then Pneumococcal, then Placebo vaccination
Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
|
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).
|
|
다른: Influenza, then Placebo, then Pneumococcal vaccination
Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo).
After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
|
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).
|
|
다른: Placebo, then Pneumococcal, then Influenza vaccination
Participants first received a 0.5 mL injection of saline (placebo).
After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
|
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).
|
|
다른: Placebo, then Influenza, then Pneumococcal vaccination
Participants first received a 0.5 mL injection of saline (placebo).
After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
|
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Vaccination (Day 0) in Mean CD4+ T Cell-associated HIV RNA Transcription at Day 7
기간: Day 0 and Day 7
|
CD4+ T cell-associated HIV RNA was measured before vaccination on Day 0 and again on Day 7. The Day-0 measure of CD4+ T cell-associated HIV RNA transcription was subtracted from the Day-7 measure.
|
Day 0 and Day 7
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 160089
- 1R01AI118422-01A1 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
에이즈에 대한 임상 시험
-
Duke UniversityGilead Sciences모병HIV 예방 | HIV 사전 노출 예방 | HIV 예방 프로그램 | HIV 예방 및 관리 | HIV 사전 노출 예방 사용미국
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)모병
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)모병
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)모병실행할 수 있음 | HIV 예방 | PrEP 흡수 | 수용 가능성 | HIV 자가 테스트 | HIV 음성 산후 여성의 남성 파트너남아프리카
-
State University of New York at BuffaloYale University Center for Interdisciplinary Research on AIDS아직 모집하지 않음HIV 예방 | HIV 테스트 | 성 및 생식 건강미국
-
Hospital Clinic of Barcelona완전한
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
Instituto Mexicano del Seguro Social모병체중 감량 | 에이즈 | HIV-1 감염 | 체중 변화 | HIV 관련 체중 감소 | 인테그라제 억제제, HIV; HIV 프로테아제 억제멕시코
-
Thomas Aagaard RasmussenAarhus University Hospital; The Alfred; Germans Trias i Pujol Hospital; Walter and Eliza Hall...모병
Fluarix에 대한 임상 시험
-
ModernaTX, Inc.완전한계절 인플루엔자미국, 대만, 영국, 독일, 벨기에, 그루지야, 불가리아, 캐나다, 에스토니아, 핀란드, 대한민국
-
GlaxoSmithKline완전한인플루엔자스페인, 체코, 영국, 폴란드
-
GlaxoSmithKline완전한